RE:BDZ - a question of RVX 208 synergies?I would expect apabetalone to have an additive effect at MACE reduction on top of most LDL-C lowering strategies (statin, bempedoic acid, ezetimibe, PCSK9 antibody, PCSK9 RNAi inclisiran). However, some (statins, bempedoic acid) but not all off these lower inflammation (i.e. hsCRP). Since apabetalone also has an anti-inflammatory component, the MACE reduction elicited by apabetalone might be less when combined with statin or bempedoic acid compared to PCSK9s and ezetimibe. As for synergy (magnitude of synergy effect greater than additive) I don't know of any evidence suggesting that Apabetalone synergizes with any LDL-C lowering therapy for MACE reduction. The apabetalone and rosuvastatin synergy was for plaque reduction, and in BETonMACE there was no apparent difference in MACE reduction elicited by apabetalone between the atorvastatin and rosuvastatin groups. I acknowledge that the low LDL-C at baseline subgroup in BETonMACE seemed to respond better to apabetalone; however, I don't understand this and haven't seen any additional info yet shedding light on this. Similarly, while the DPP4 inhibitor and SGLT2 inhibitor synergies for MACE reduction look impressive, I also haven't seen any hypotheses floating around for the potential mechanism of these synergies. SGLT2 inhibitors and DPP4 inhibitors act through completely different mechanisms. Pooling these synergies together is an oversimplification in my opinion. BDAZ